Pfizer Inc. (PFE) Thursday announced positive efficacy and safety data for Abrysvo vaccine against respiratory syncytial virus or RSV in adults 60 years of age and older through two full RSV seasons.
The company said no new adverse events were reported through the second RSV season.
According to Pfizer, the new data indicate broad and durable protection against both types of RSV that cause disease, RSV A and RSV B.
RSV is a contagious virus and a common cause of respiratory illness that can affect the lungs and breathing passages.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.